In our retrospective, non-randomized, multicenter study, we tried to assess the usefulness of TS, MTHFR and ERCC1 genes polymorphisms detected in venous blood cells as molecular predictive markers for first-line pemetrexed and platinum therapy in NSCLC patients. This evidence concerns the gene MTHFR and non-small cell lung carcinoma.